title: Arthritis occurrence or reactivation under Vedolizumab treatment for inflammatory bowel disease. A four cases report.
authors.affiliation: Rheumatology, CHRU de Besançon, 25030 Besançon, France; Université de Franche-Comté, 25030 Besançon, France. Electronic address: dwendling@chu-besancon.fr.
authors.forename: Daniel
authors.initials: D
authors.lastname: Wendling
authors.affiliation: Rheumatology, CHRU de Besançon, 25030 Besançon, France; Université de Franche-Comté, 25030 Besançon, France.
authors.forename: Maxime
authors.initials: M
authors.lastname: Sondag
authors.affiliation: Rheumatology, CHRU de Besançon, 25030 Besançon, France; Université de Franche-Comté, 25030 Besançon, France.
authors.forename: Frank
authors.initials: F
authors.lastname: Verhoeven
authors.affiliation: Université de Franche-Comté, 25030 Besançon, France; Gastroenterology, CHRU de Besançon, 25030 Besançon, France.
authors.forename: Lucine
authors.initials: L
authors.lastname: Vuitton
authors.affiliation: Université de Franche-Comté, 25030 Besançon, France; Gastroenterology, CHRU de Besançon, 25030 Besançon, France.
authors.forename: Stephane
authors.initials: S
authors.lastname: Koch
authors.affiliation: Rheumatology, CHRU de Besançon, 25030 Besançon, France; Université de Franche-Comté, 25030 Besançon, France.
authors.forename: Clément
authors.initials: C
authors.lastname: Prati
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D001168:Arthritis / Q000139:chemically induced* / Q000503:physiopathology; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D015212:Inflammatory Bowel Diseases / Q000175:diagnosis / Q000188:drug therapy*; D008875:Middle Aged; D012494:Sampling Studies; D025241:Spondylarthritis / Q000139:chemically induced* / Q000453:epidemiology / Q000503:physiopathology; D055815:Young Adult
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C543529:vedolizumab
keywords: Arthritis; Inflammatory bowel disease; Spondyloarthritis; Vedolizumab